MedTrace Logo

Neoadjuvant Stereotactic Radiotherapy for Brain Metastasis

NCT06933199 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2025-05-04

No results posted yet for this study

Summary

This multicentre proof-of-concept study, involving 4 centers, aims to establish the value of fractionated neoadjuvant stereotactic radiotherapy (NaSRT) as a new treatment paradigm for brain metastases (BM) in the frame of the Czech neurooncology network. Most relevant studies published to date used single-fraction radiotherapy and dealt with the inherent bias related to their retrospective nature. The researchers aim to increase the level of evidence for this treatment paradigm together with other similar ongoing studies.

Conditions

Interventions

RADIATION

Neoadjuvant Stereotactic Radiotherapy (NaSRT)

Neoadjuvant Stereotactic Radiotherapy (NaSRT) gives radiotherapy before surgery from many different angles around the body. The beams meet at the tumor. This means the tumor receives a high dose of radiation and the tissues around it receive a much lower dose. This lowers the risk of side effects.

RADIATION

Postoperative Stereotactic Radiotherapy (SRT)

Postoperative Stereotactic Radiotherapy (SRT) gives radiotherapy after surgery from many different angles around the body. The beams meet at the tumor. This means the tumor receives a high dose of radiation and the tissues around it receive a much lower dose. This lowers the risk of side effects.

Sponsors & Collaborators

  • University Hospital Olomouc

    collaborator OTHER

  • Masaryk Memorial Cancer Institute

    collaborator OTHER

  • University Hospital Hradec Kralove

    collaborator OTHER

  • University Hospital Ostrava

    lead OTHER

Principal Investigators

  • Jakub Cvek, Assoc.Prof., MD, Ing, PhD, MBA · University Hospital Ostrava

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-01
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06933199 on ClinicalTrials.gov